The Ghost in the Machine: Why Radiopharmaceutical Talent is the New Gold Standard
For more than a decade, I’ve operated at the intersection of talent and strategy in the life sciences. I’ve had a front-row seat to the rise of new therapeutic modalities, from cell therapies to gene editing. I thought I had seen it all. Then came the radiopharmaceutical “gold rush.” It started, as it often does, […]